RNXT
RenovoRx, Inc.
$0.8440
-2.43%
$38.1M
No data for this timeframe.
Vol
Market Cap$38.1M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders11 funds
Inst. Value$2.0M
Inst. Activity2 buys / 1 sells
Insider Activity7B / 0S
Insider Net $$19.7K
SEC Reports8
Press Releases6
Recent Activity
Jun 4, 2026
other
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
<p align="justify">MOUNTAIN VIEW, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.g
May 26, 2026
Press
RenovoRx announced the publication of a PK/PD sub-study from its Phase III TIGeR-PaC trial at ASCO 2026, showing that in
Impact 5/10
May 19, 2026
SEC
RenovoRx announced management participation in an AGP healthcare showcase and highlighted record Q1 2026 RenovoCath reve
PRESS-RELEASE — Impact 3/10
May 19, 2026
Insider
VOLL MARK bought 25,000 shares
Chief Financial Officer @ $0.7876 ($19.7K)
May 15, 2026
SEC
RenovoRx filed Amendment No. 1 to its 2025 10-K solely to revise risk factor disclosures (Item 1A) and add missing contr
10-K/A — Impact 4/10
May 14, 2026
SEC
RenovoRx reported Q1 2026 revenue of $563,000, a 136% sequential increase from Q4 2025 and exceeding 50% of full-year 20
8-K — Impact 5/10
Apr 3, 2026
Insider
Agah Ramtin was granted 621,727 shares
Chief Medical Officer
Apr 3, 2026
Insider
Gentry Leesa was granted 128,550 shares
Chief Clinical Officer
Price Targets
$7.03
+733.1% upside
Strong Buy
Current $0.8438
Low $3.00
Median $5.56
High $14.00
4 analysts
$3.00
$14.00
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 1, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Apr 9, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Apr 8, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 17, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.07 ▲ +2.2% | $-0.08 — $-0.07 | 6% YoY | 2 |
| Next Q | $-0.07 ▼ -7.1% | $-0.08 — $-0.07 | 6% YoY | 2 |
| Current FY | $-0.31 ▼ -8.1% | $-0.33 — $-0.29 | 3% YoY | 2 |
| Next FY | $-0.15 ▼ -25.0% | $-0.27 — $-0.03 | 52% YoY | 2 |
Latest Reports
BULLISH
Press
5/10
RenovoRx announced the publication of a PK/PD sub-study from its Phase III TIGeR-PaC trial at ASCO 2026, showing that in
May 26, 2026
NEUTRAL
PRESS-RELEASE
3/10
RenovoRx announced management participation in an AGP healthcare showcase and highlighted record Q1 2026 RenovoCath reve
May 19, 2026
NEUTRAL
10-K/A
4/10
RenovoRx filed Amendment No. 1 to its 2025 10-K solely to revise risk factor disclosures (Item 1A) and add missing contr
May 15, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.5M | — |
| CITADEL ADVISORS LLC | $235.0K | — |
| VANGUARD FIDUCIARY TRUST CO | $159.5K | — |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT | $100.5K | — |
| STATE STREET CORP | $26.4K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 19, 2026 | VOLL MARK | BUY | $19.7K |
| Apr 3, 2026 | Agah Ramtin | A | $0.00 |
| Apr 3, 2026 | Gentry Leesa | A | $0.00 |
| Apr 3, 2026 | Bagai Shaun | A | $0.00 |
| Apr 3, 2026 | VOLL MARK | A | $0.00 |
11 institutional holders with $2.0M total value (2,062,821 shares) as of 2026-Q1. Top holders: VANGUARD, CITADEL, VANGUARD. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1,447,177 | $1.5M | 71.7% | — |
| 2 | CITADEL ADVISORS LLC | 232,684 | $235.0K | 11.5% | — |
| 3 | VANGUARD FIDUCIARY TRUST CO | 157,902 | $159.5K | 7.8% | — |
| 4 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 99,460 | $100.5K | 4.9% | — |
| 5 | STATE STREET CORP | 26,152 | $26.4K | 1.3% | — |
| 6 | HighTower Advisors, LLC | 20,000 | $20.2K | 1.0% | — |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 13,000 | $13.1K | 0.6% | NEAR_EXIT -88.9% |
| 8 | CAPTRUST FINANCIAL ADVISORS | 12,307 | $12.4K | 0.6% | — |
| 9 | MORGAN STANLEY | 7,102 | $7.2K | 0.4% | DOUBLED +533.5% |
| 10 | CITIGROUP INC | 3,917 | $4.0K | 0.2% | — |
| 11 | HRT FINANCIAL LP | 43,120 | $43.00 | 0.0% | DOUBLED +302.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 117,457 | 13,000 | -88.9% | $13.1K | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 1,121 | 7,102 | +533.5% | $7.2K | 2026-Q1 |
| HRT FINANCIAL LP | DOUBLED | 10,726 | 43,120 | +302.0% | $43.00 | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 313,550 | 117,457 | -62.5% | $98.7K | 2025-Q4 |
| HRT FINANCIAL LP | TRIM | 24,770 | 10,726 | -56.7% | $9.00 | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 30,009 | 671 | -97.8% | $852.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 27,656 | 251,800 | +810.5% | $331.1K | 2025-Q2 |
| UBS Group AG | TRIM | 66,732 | 30,009 | -55.0% | $39.5K | 2025-Q2 |
| UBS Group AG | DOUBLED | 12,266 | 66,732 | +444.0% | $66.1K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 64,900 | 27,656 | -57.4% | $27.4K | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 196 | 304 | +55.1% | $301.00 | 2025-Q1 |
| VANGUARD GROUP INC | DOUBLED | 56,737 | 141,487 | +149.4% | $182.5K | 2024-Q4 |
| UBS Group AG | DOUBLED | 2,236 | 12,266 | +448.6% | $15.8K | 2024-Q4 |
5 unique insiders with 12 transactions. Net insider value: $19.7K ($19.7K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 19, 2026 | VOLL MARK | Chief Financial Officer | BUY | 25,000 | $0.7876 | $19.7K |
| Apr 3, 2026 | Agah Ramtin | Chief Medical Officer | AWARD | 621,727 | — | — |
| Apr 3, 2026 | Gentry Leesa | Chief Clinical Officer | AWARD | 128,550 | — | — |
| Apr 3, 2026 | Bagai Shaun | Chief Executive Officer | AWARD | 946,107 | — | — |
| Apr 3, 2026 | VOLL MARK | Chief Financial Officer | AWARD | 80,000 | — | — |
| Mar 25, 2026 | VOLL MARK | Chief Financial Officer | AWARD | 12,380 | — | — |
| Mar 20, 2026 | Bagai Shaun | Chief Executive Officer | BUY | 12,150 | — | — |
| Mar 20, 2026 | VOLL MARK | Chief Financial Officer | BUY | 97,200 | — | — |
| Mar 20, 2026 | Marton Laurence | Director | BUY | 4,860 | — | — |
| Mar 20, 2026 | VOLL MARK | Chief Financial Officer | BUY | 48,600 | — | — |
| Mar 20, 2026 | Bagai Shaun | Chief Executive Officer | BUY | 24,300 | — | — |
| Mar 20, 2026 | Marton Laurence | Director | BUY | 9,720 | — | — |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 6 neutral. Avg impact: 4.0/10.
NEUTRAL
PRESS-RELEASE
3/10
RenovoRx announced management participation in an AGP healthcare showcase and highlighted record Q1
May 19, 2026
NEUTRAL
10-K/A
4/10
RenovoRx filed Amendment No. 1 to its 2025 10-K solely to revise risk factor disclosures (Item 1A) a
May 15, 2026
BULLISH
8-K
5/10
RenovoRx reported Q1 2026 revenue of $563,000, a 136% sequential increase from Q4 2025 and exceeding
May 14, 2026
NEUTRAL
PRESS-RELEASE
3/10
RenovoRx announced its Q1 2026 earnings conference call for May 14, 2026, with no financial results
Apr 29, 2026
NEUTRAL
EFFECT
4/10
RenovoRx's S-3 shelf registration (File No. 333-295108) became effective on April 27, 2026. This all
Apr 28, 2026
MIXED
8-K
6/10
RenovoRx reported full-year 2025 revenue of $1.1 million, a significant increase from $43,000 in 202
Apr 21, 2026
NEUTRAL
S-3
4/10
RenovoRx filed an S-3 shelf registration to allow resale of up to 15.96 million shares by selling st
Apr 16, 2026
NEUTRAL
3/A
3/10
Mark Voll, newly appointed CFO of RenovoRx, filed an amended Form 3/A to correct his title after pre
Mar 27, 2026
BULLISH
5/10
RenovoRx announced the publication of a PK/PD sub-study from its Phase III TIGeR-PaC trial at ASCO 2
May 26, 2026
BULLISH
7/10
RenovoRx announced clinical data presented at SIR 2026 showing TAMP, enabled by its RenovoCath devic
Apr 14, 2026
MIXED
6/10
RenovoRx reported $1.1 million in revenue for 2025, its first full year of commercialization, up fro
Mar 30, 2026
NEUTRAL
5/10
RenovoRx closed an oversubscribed private placement raising $10 million in gross proceeds through th
Mar 23, 2026
NEUTRAL
4/10
RenovoRx announced it will host a conference call on March 30, 2026, to discuss its Q4 and full-year
Mar 20, 2026
NEUTRAL
5/10
RenovoRx (RNXT) announced an oversubscribed private placement expected to raise approximately $10 mi
Mar 18, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.03 mean target
+733.1% upside
Strong Buy (1.00)
$3.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $0.8438 |
| Target Low | $3.00 |
| Target Mean | $7.03 |
| Target Median | $5.56 |
| Target High | $14.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.07 | $-0.08 | $-0.07 | 6.3% | +2.2% | 0↑ 1↓ | $0.0B | 66.8% | 2 |
| Next Q 2026-09-30 |
$-0.07 | $-0.08 | $-0.07 | 6.3% | -7.1% | 1↑ 1↓ | $0.0B | 205.1% | 2 |
| Current FY 2026-12-31 |
$-0.31 | $-0.33 | $-0.29 | 3.1% | -8.1% | 1↑ 1↓ | $0.0B | 185.5% | 2 |
| Next FY 2027-12-31 |
$-0.15 | $-0.27 | $-0.03 | 51.6% | -25.0% | 0↑ 2↓ | $0.0B | 283.4% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.075 | |
| 7d ago | $-0.080 | +0.005 |
| 30d ago | $-0.077 | +0.002 |
| 60d ago | $-0.070 | -0.005 |
| 90d ago | $-0.073 | -0.002 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 1, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Apr 9, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 17, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
other
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
<p align="justify">MOUNTAIN VIEW, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=C6cVHDnIdELmuCoqzCuy
May 28, 2026
other
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity <pre>Th
May 26, 2026
fda
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
<p align="center"><em>Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Dem
May 19, 2026
earnings
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
<p align="justify">MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=qxbj69pR4KuVjXSmMEn44
May 14, 2026
earnings_calendar
RNXT Q1 2026 Earnings Scheduled — 2026-05-14
Apr 29, 2026
earnings
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
<p align="justify">MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=CoBPGTAu1QQqcEAgZ_V
Apr 14, 2026
fda
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
<p align="center"><em>Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnose
Apr 8, 2026
other
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
<p align="center"><em>Patent Expands Protection for the Company’s RenovoCath Device, the Novel Dual-Occlusion Catheter-Based System </em></p>
Apr 1, 2026
other
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More <pre>RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More</pre>
Mar 30, 2026
earnings
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
<p align="center"><em>RenovoCath</em><sup><em>®</em></sup><em> Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization</em></p>
Mar 30, 2026
earnings_calendar
RNXT Q4 2025 Earnings Before Market Open — 2026-03-30
Mar 26, 2026
fda
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
<p align="center"><em>TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027</em></p>
Mar 23, 2026
offering
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
Company has the funding, business plan, leadership and infrastructure to propel achievement of upcoming commercial and clinical milestones <pre>Compan
Mar 20, 2026
earnings
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
<p align="justify">MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=JfnLmhIfJnCPfxChCKu
Mar 18, 2026
offering
RenovoRx Announces $10 Million at Market Private Placement
<p align="center"><em>Bolstered Cash Position Expected to Capitalize the Company’s Momentum Towards Important Milestones, Including Breakeven Operatio